Is it reasonable to propose vaginal delivery with twin pregnancies, when the first twin is in breech presentation?


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
May 2022
Historique:
received: 23 09 2021
revised: 03 04 2022
accepted: 07 04 2022
pubmed: 12 4 2022
medline: 4 5 2022
entrez: 11 4 2022
Statut: ppublish

Résumé

Breech presentation of the first twin occurs in 20% of twin pregnancies. However, the impact of delivery mode on morbimortality in breech fetuses remains controversial in the literature generally, and has been infrequently studied in twin pregnancies specifically. The aim herein was to evaluate neonatal and maternal outcomes according to delivery mode when the first twin was in breech presentation, and to compare these results with those in the current literature. This was a single-center, retrospective study in Lille, France, from January 2010 to December 2017, including twin pregnancies in which the first twin was in breech presentation and delivery was after 32 weeks of amenorrhea. Two groups were defined: planned vaginal delivery (PVD) and planned cesarean delivery (PCD). The primary outcome was neonatal morbidities, defined as a 5-minute Apgar score < 7, cord pH < 7.10 at birth, sepsis, and acute respiratory distress syndrome. Among the 184 patients included, 116 attempted a vaginal delivery (63%). Morbidity did not differ between PVD and PCD for the first twin (12/116 (10.3%) versus 7/68 (10.3%), respectively, p = 0.99), the second twin (18/116 (15.5%) versus 7/68 (10.3%), respectively, p = 0.31), or either twin (27/116 (23.2%) versus 11/68 (16.2%), respectively, p = 0.25). The rate of postpartum hemorrhage was significantly lower in the PVD group (PVD 36/116 (31%) versus PCD 41/68 (58.8%), p = 0.001). PVD is a reasonable option when the first twin is in breech presentation with probably no higher neonatal mortality and morbidity and less risk of maternal severe postpartum hemorrhage.

Sections du résumé

BACKGROUND BACKGROUND
Breech presentation of the first twin occurs in 20% of twin pregnancies. However, the impact of delivery mode on morbimortality in breech fetuses remains controversial in the literature generally, and has been infrequently studied in twin pregnancies specifically. The aim herein was to evaluate neonatal and maternal outcomes according to delivery mode when the first twin was in breech presentation, and to compare these results with those in the current literature.
MATERIAL AND METHODS METHODS
This was a single-center, retrospective study in Lille, France, from January 2010 to December 2017, including twin pregnancies in which the first twin was in breech presentation and delivery was after 32 weeks of amenorrhea. Two groups were defined: planned vaginal delivery (PVD) and planned cesarean delivery (PCD). The primary outcome was neonatal morbidities, defined as a 5-minute Apgar score < 7, cord pH < 7.10 at birth, sepsis, and acute respiratory distress syndrome.
RESULTS RESULTS
Among the 184 patients included, 116 attempted a vaginal delivery (63%). Morbidity did not differ between PVD and PCD for the first twin (12/116 (10.3%) versus 7/68 (10.3%), respectively, p = 0.99), the second twin (18/116 (15.5%) versus 7/68 (10.3%), respectively, p = 0.31), or either twin (27/116 (23.2%) versus 11/68 (16.2%), respectively, p = 0.25). The rate of postpartum hemorrhage was significantly lower in the PVD group (PVD 36/116 (31%) versus PCD 41/68 (58.8%), p = 0.001).
CONCLUSION CONCLUSIONS
PVD is a reasonable option when the first twin is in breech presentation with probably no higher neonatal mortality and morbidity and less risk of maternal severe postpartum hemorrhage.

Identifiants

pubmed: 35405373
pii: S2468-7847(22)00067-8
doi: 10.1016/j.jogoh.2022.102377
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102377

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

L Ghesquière (L)

Univ. Lille, CHU Lille, ULR 2694, METRICS-Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France; CHU Lille, Department of Obstetrics, F-59000 Lille, France. Electronic address: Louise.ghesquiere@chru-lille.fr.

J Rouilles (J)

CHU Lille, Department of Obstetrics, F-59000 Lille, France.

E Drumez (E)

CHU Lille, Department of Biostatistic, F-59000 Lille, France.

V Houfflin-Debarge (V)

Univ. Lille, CHU Lille, ULR 2694, METRICS-Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France; CHU Lille, Department of Obstetrics, F-59000 Lille, France.

D Subtil (D)

Univ. Lille, CHU Lille, ULR 2694, METRICS-Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France; CHU Lille, Department of Obstetrics, F-59000 Lille, France.

C Garabedian (C)

Univ. Lille, CHU Lille, ULR 2694, METRICS-Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France; CHU Lille, Department of Obstetrics, F-59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH